FoxPlug

Healthcare and biotech startup launches

21 companies on the record below, and 28 with a launch page of their own. Every line links to the record it was read from.

Healthcare and biotech launch pages

  • Allia Health
    Clinically Integrated Group for Mental Health
  • Atlas Discovery
    AI-native pharma company
  • Avoca Systems
    The AI-powered operating system for radiology networks
  • Care GP
    AI agents to run primary healthcare operations
  • Cova
    Financial infrastructure for family caregiving
  • Elite
    AI voice agents that run the healthcare front office.
  • Evergrove
    Voice agents that accelerate care coordination in workers' comp
  • Floracene
    Vibecode + deploy HIPAA-compliant internal tools, no eng team needed
  • Gamgee
    Scalable Personalised Cancer Treatment
  • Gutgutgoose
    We sequence your gut and build the probiotics it’s missing
  • Halmos Labs
    Maximum information per experiment, minimum experiments per conclusion
  • Hubble
    Retrieve records other APIs can't
  • Illume Labs
    24/7 Personal Health & Longevity Companion
  • Infera
    Control lab instruments with natural language.
  • Insurf
    The AI-Native Decision Layer for Health Insurance
  • Lattice Health
    Monitoring and governance for deployed medical imaging AI
  • Lumeria
    Oura Ring for Skin
  • Nxtcure Labs
    The full-stack AI CRO for drug discovery.
  • Omanta
    A research lab for one
  • Panacea
    AI-Native FDA Regulatory Services
  • Plena Health
    Plena is the AI operating system for specialty medical practices
  • Prescience, Inc.
    Health insurance for the age of abundant intelligence.
  • Radley
    The AI-native radiology practice
  • Rasyn
    Making chemicals 100,000x faster
  • RonanRx Inc.
    Full Stack Pharmaceutical Company for Personalized Peptides and GLP-1s
  • TareBio
    Vaccines for any cancer or infection in weeks.
  • Voquill
    The agentic OS for medical labs
  • WonderTx
    Extrapolative AI to unlock First-in-Class drugs

Airway Therapeutics, Inc.

Who is behind it

  • Marc Salzberg: executive officer and director named in the Form D (Chairman and Chief Executive Officer). (source)
  • Alan Wolk: executive officer and director named in the Form D (Chief Financial Officer, Chief Operating Officer, Treasurer and Secretary). (source)
  • Doug Loftus: director named in the Form D. (source)
  • Elise Scroggs Panayotopoulous: director named in the Form D. (source)
  • Joe Todicsco: director named in the Form D. (source)
  • Has a careers page at https://www.airwaytherapeutics.com/careers. (source)

Funding on file

  • The Form D filed on 2026-09-09 reports a $50,584,517 offering, $43,496,282 sold, $7,088,235 remaining, from 116 investors so far, all accredited. (source)
  • Terms in the filing: securities offered: equity, options or warrants, securities issued on exercise of options; exemption claimed: Rule 506(b); offering expected to last more than a year: no. (source)
  • Issuer: Corporation organised in Delaware, incorporated more than five years before the filing; principal office listed in Marietta, Georgia; revenue range: decline to disclose. (source)

Timeline

  1. 2026-08-10: first sale in the offering, per the Form D. (source)
  2. 2026-09-09: Form D filed with the SEC ($43.50M sold). (source)

airwaytherapeutics.com ↗

ALZHEON, INC.

What they shipped

  • Its own site describes it as: "Alzheon is committed to developing breakthrough medicines for patients suffering from Alzheimer's disease and other neurological disorders." (source)
  • Homepage headline: "Preserving future memories" (source)

Who is behind it

  • Martin Tolar, M.D., Ph.D.: executive officer and director named in the Form D (President and Chief Executive Officer). (source)
  • Christopher Noel Dunn: director named in the Form D. (source)
  • Neil W. Flanzraich: director named in the Form D. (source)
  • Jordan Heller: director named in the Form D. (source)
  • Diane K. Jorkasky, M.D.: director named in the Form D. (source)
  • Gino Santini: director named in the Form D. (source)
  • Muneer Satter: director named in the Form D. (source)
  • Kenneth Mace: executive officer named in the Form D (Treasurer and Chief Financial Officer). (source)
  • Has a careers page at https://alzheon.com/careers. (source)

Funding on file

  • The Form D filed on 2026-09-10 reports a $499,999,999 offering, $78,797,184 sold, $421,202,815 remaining, from 3 investors so far, all accredited. (source)
  • Terms in the filing: securities offered: equity; exemption claimed: Rule 506(b); offering expected to last more than a year: yes. (source)
  • Issuer: Corporation organised in Delaware, incorporated more than five years before the filing; principal office listed in Framingham, Massachusetts; revenue range: decline to disclose. (source)

Timeline

  1. 2026-08-26: first sale in the offering, per the Form D. (source)
  2. 2026-09-10: Form D filed with the SEC ($78.80M sold). (source)

alzheon.com ↗

DAVION HEALTHCARE PLC

Who is behind it

  • Jack Harry Kaye: executive officer and director named in the Form D. (source)

Funding on file

  • The Form D filed on 2026-09-08 reports a $10,000,000 offering, $350,000 sold, $9,650,000 remaining, from 3 investors so far, all accredited. (source)
  • Terms in the filing: securities offered: debt; minimum investment accepted: $50,000; exemption claimed: Rule 506(b); offering expected to last more than a year: no. (source)
  • Issuer: Corporation organised in Cyprus, incorporated in 2024; principal office listed in Clonakilty, Ireland; revenue range: no revenues. (source)
  • Sales compensation recipient: Vienna Capital Partners LLC (CRD 000311852). (source)
  • Sales commissions $800,000 and finders' fees $0 reported in the filing. (source)

Timeline

  1. 2026-08-26: first sale in the offering, per the Form D. (source)
  2. 2026-09-08: Form D filed with the SEC ($350K sold). (source)

davionhealthcare.com ↗

DexCare, Inc.

What they shipped

  • Its own site describes it as: "DexCare is infrastructure for patient navigation and scheduling to grow patient volume without adding clinical resources. The platform connects data across EMRs, workflows, and access points so health systems route patients to available care, regardless of where they enter or what modality they need. The problem? Capacity exists but systems can't see it. Results: 40% more patients treated and" (source)
  • Homepage headline: "Meet Mila ." (source)

Who is behind it

  • Matthew Blosl: executive officer and director named in the Form D. (source)
  • Lynne Chou O'Keefe: director named in the Form D. (source)
  • Toby Cosgrove: director named in the Form D. (source)
  • Todd Cozzens: director named in the Form D. (source)
  • Branden Fini: director named in the Form D. (source)
  • Paul Minardi: director named in the Form D. (source)
  • Caroline Xie: director named in the Form D. (source)
  • Has a careers page at https://dexcare.com/careers. (source)

Funding on file

  • The Form D filed on 2026-09-14 reports a $22,724,666 offering, $12,929,562 sold, $9,795,104 remaining, from 14 investors so far, all accredited. (source)
  • Terms in the filing: securities offered: equity; exemption claimed: Rule 506(b); offering expected to last more than a year: yes. (source)
  • Issuer: Corporation organised in Delaware, incorporated more than five years before the filing; principal office listed in Seattle, Washington; revenue range: decline to disclose. (source)

Timeline

  1. 2026-08-28: first sale in the offering, per the Form D. (source)
  2. 2026-09-14: Form D filed with the SEC ($12.93M sold). (source)

dexcare.com ↗

DynamiCare Health, Inc.

What they shipped

  • Its own site describes it as: "Our evidence-based telehealth program helps people recover from or reduce their use of addictive substances, including alcohol, drugs, and nicotine." (source)
  • Homepage headline: "Transforming Addiction Recovery with Proven Digital Health" (source)

Who is behind it

  • David Robert Gastfriend: executive officer and director and promoter named in the Form D. (source)
  • Eric Elias Gastfriend: director named in the Form D (Left board upon closing.). (source)
  • Benjamin Blum: director named in the Form D (Left board upon closing.). (source)
  • Kelley Bowker: executive officer named in the Form D (Was no longer CEO at time of closing.). (source)

Funding on file

  • The Form D filed on 2026-09-10 reports a $1,500,000 offering, $720,000 sold, $780,000 remaining, from 6 investors so far, all accredited. (source)
  • Terms in the filing: securities offered: equity; exemption claimed: Rule 506(b); offering expected to last more than a year: no. (source)
  • Issuer: Corporation organised in Delaware, incorporated more than five years before the filing; principal office listed in Boston, Massachusetts; revenue range: decline to disclose. (source)

Timeline

  1. 2026-08-25: first sale in the offering, per the Form D. (source)
  2. 2026-09-10: Form D filed with the SEC ($720K sold). (source)

dynamicarehealth.com ↗

ENCISION INC

Who is behind it

  • Vern D. Kornelsen: director named in the Form D. (source)
  • Robert H. Fries: executive officer and director named in the Form D. (source)

Funding on file

  • The Form D filed on 2026-09-17 reports a $80,000 offering, $80,000 sold, $0 remaining, from 2 investors so far, all accredited. (source)
  • Terms in the filing: securities offered: equity; exemption claimed: Rule 506(b); offering expected to last more than a year: no. (source)
  • Issuer: Corporation organised in Colorado, incorporated more than five years before the filing; principal office listed in Boulder, Colorado; revenue range: $5,000,001 - $25,000,000. (source)

Timeline

  1. 2026-09-08: first sale in the offering, per the Form D. (source)
  2. 2026-09-17: Form D filed with the SEC ($80K sold). (source)

encision.com ↗

Gliknik Inc

Who is behind it

  • David S. Block: executive officer and director named in the Form D. (source)
  • Charles Polsky: director named in the Form D. (source)
  • Kyle Rusconi: director named in the Form D. (source)
  • Raymond Schinazi: director named in the Form D. (source)
  • Richard S. Levy: director named in the Form D. (source)
  • Paul Freidman: director named in the Form D. (source)
  • Elizabeth Block: executive officer named in the Form D. (source)
  • David Broser: director named in the Form D. (source)

Funding on file

  • The amended Form D filed on 2026-09-17 reports a $15,000,000 offering, $15,000,000 sold, $0 remaining, from 11 investors so far, all accredited. (source)
  • Terms in the filing: securities offered: debt, options or warrants, securities issued on exercise of options; exemption claimed: Rule 506(b); offering expected to last more than a year: yes. (source)
  • Issuer: Corporation organised in Delaware, incorporated more than five years before the filing; principal office listed in Baltimore, Maryland; revenue range: decline to disclose. (source)

Timeline

  1. 2025-08-15: first sale in the offering, per the Form D. (source)
  2. 2026-09-17: Form D amendment filed with the SEC ($15.00M sold). (source)

gliknik.com ↗

Gossamer Bio, Inc.

What they shipped

  • Homepage description: "Science Seralutinib Seralutinib is an inhaled PDGFRα/β, CSF1R, and c‑KIT inhibitor designed to be delivered via dry powder inhaler for the potential treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)." (source)

Who is behind it

  • Faheem Hasnain: executive officer and director named in the Form D. (source)
  • Russell Cox: director named in the Form D. (source)
  • Thomas Daniel: director named in the Form D. (source)
  • Skye J. Drynan: director named in the Form D. (source)
  • Sandra Milligan: director named in the Form D. (source)
  • Steven D. Nathan: director named in the Form D. (source)
  • John Quisel: director named in the Form D. (source)
  • Bryan Giraudo: executive officer named in the Form D. (source)

Funding on file

  • The Form D filed on 2026-09-04 reports a $150,000,000 offering, $25,000,000 sold, $125,000,000 remaining, from 38 investors so far, all accredited. (source)
  • Terms in the filing: securities offered: options or warrants, securities issued on exercise of options; exemption claimed: Rule 506(b); offering expected to last more than a year: no. (source)
  • Issuer: Corporation organised in Delaware, incorporated more than five years before the filing; principal office listed in San Diego, California; revenue range: decline to disclose. (source)
  • Sales compensation recipient: Leerink Partners LLC (CRD 39011). (source)
  • Sales compensation recipient: Cantor Fitzgerald & Co. (CRD 134). (source)
  • Sales commissions $1,375,000 and finders' fees $0 reported in the filing. (source)

Timeline

  1. 2026-08-20: first sale in the offering, per the Form D. (source)
  2. 2026-09-04: Form D filed with the SEC ($25.00M sold). (source)

gossamerbio.com ↗

Hexamer Therapeutics, Inc

What they shipped

  • Its own site describes it as: "Innovators in natural vaccine technology. Explore rapidly engineered, scalable vaccine technologies at Hexamer Therapeutics." (source)
  • Homepage headline: "Developing a new generation of vaccine technologies" (source)

Who is behind it

  • Robert H Bogden: executive officer and director named in the Form D. (source)
  • Colin Collins: director named in the Form D. (source)
  • Keith Miller: director named in the Form D. (source)
  • R. Scott Blackley: director named in the Form D. (source)
  • Stephen Crawford: director named in the Form D. (source)
  • Brad Call: director named in the Form D. (source)

Funding on file

  • The Form D filed on 2026-09-15 reports a $2,500,000 offering, $500,000 sold, $2,000,000 remaining, from 2 investors so far, all accredited. (source)
  • Terms in the filing: securities offered: equity, options or warrants; exemption claimed: Rule 506(b); offering expected to last more than a year: no. (source)
  • Issuer: Corporation organised in Delaware, incorporated more than five years before the filing; principal office listed in Pullman, Washington; revenue range: decline to disclose. (source)

Timeline

  1. 2026-07-07: first sale in the offering, per the Form D. (source)
  2. 2026-09-15: Form D filed with the SEC ($500K sold). (source)

hexamertherapeutics.com ↗

Iambic Therapeutics, Inc.

What they shipped

  • Its own site describes it as: "Iambic has created a cutting-edge AI-driven platform to tackle the most challenging design problems in drug discovery and address unmet patient need." (source)

Who is behind it

  • Thomas Miller: executive officer and director named in the Form D. (source)
  • Fred Manby: executive officer and director named in the Form D. (source)
  • Neil Josephson: executive officer named in the Form D. (source)
  • Michael Secora: executive officer named in the Form D. (source)
  • Jishnu Bhattacharjee: director named in the Form D. (source)
  • Evan Rachlin: director named in the Form D. (source)
  • R. Jacob Vogelstein: director named in the Form D. (source)
  • Mary Tagliaferri: director named in the Form D. (source)
  • Has a careers page at https://www.iambic.ai/careers. (source)

Funding on file

  • The Form D filed on 2026-09-09 reports a $66,500,000 offering, $65,965,000 sold, $535,000 remaining, from 16 investors so far, all accredited. (source)
  • Terms in the filing: securities offered: debt; exemption claimed: Rule 506(b); offering expected to last more than a year: no. (source)
  • Issuer: Corporation organised in Delaware, incorporated more than five years before the filing; principal office listed in San Diego, California; revenue range: decline to disclose. (source)

Timeline

  1. 2026-08-14: first sale in the offering, per the Form D. (source)
  2. 2026-09-09: Form D filed with the SEC ($65.97M sold). (source)

iambic.ai ↗

Immunophotonics, Inc.

What they shipped

  • Its own site describes it as: "Immunophotonics' proprietary glycan polymer enhances antigen capture & immune processes, unlocking platform potential for immunotherapy." (source)

Who is behind it

  • Alexander Michael Hurst: executive officer named in the Form D. (source)
  • Robert H. Arch: executive officer named in the Form D. (source)
  • Miguel M. Zubizarreta: director named in the Form D. (source)
  • Luciano Alleruzzo: director and promoter named in the Form D. (source)
  • Jonathan Knowles: director named in the Form D. (source)
  • Wei Chen: director and promoter named in the Form D. (source)
  • Jacqueline Hess: director named in the Form D. (source)
  • Richard Levenson: director named in the Form D. (source)
  • Has a careers page at https://immunophotonics.com/careers. (source)

Funding on file

  • The Form D filed on 2026-09-04 reports an offering of indefinite size, $10,147,612 sold, from 45 investors so far, some of them non-accredited. (source)
  • Terms in the filing: securities offered: equity; minimum investment accepted: $100,000; exemption claimed: Rule 506(b); offering expected to last more than a year: yes. (source)
  • Issuer: Corporation organised in Delaware, incorporated more than five years before the filing; principal office listed in St. Louis, Missouri; revenue range: decline to disclose. (source)

Timeline

  1. 2025-07-14: first sale in the offering, per the Form D. (source)
  2. 2026-09-04: Form D filed with the SEC ($10.15M sold). (source)

immunophotonics.com ↗

INTELLIGENT BIO SOLUTIONS INC.

What they shipped

  • Its own site describes it as: "Intelligent Bio Solutions (INBS) is pioneering innovative, non-invasive, real-time point-of-care testing solutions." (source)
  • Homepage headline: "Pioneering Pain-free Solutions" (source)

Who is behind it

  • Harry Simeonidis: executive officer named in the Form D (Chief Executive Officer). (source)
  • Spiro Sakiris: executive officer named in the Form D (Chief Financial Officer). (source)
  • Steven Boyages: director named in the Form D (Director). (source)
  • Jonathan Hurd: director named in the Form D (Director). (source)
  • Jason Isenberg: director named in the Form D (Director). (source)
  • Nicola Fraser: director named in the Form D (Director). (source)

Funding on file

  • The Form D filed on 2026-09-14 reports a $4,979,631 offering, $4,979,631 sold, $0 remaining, from 1 investor so far, all accredited. (source)
  • Terms in the filing: securities offered: equity, options or warrants; exemption claimed: Rule 506(b); offering expected to last more than a year: no. (source)
  • Issuer: Corporation organised in Delaware, incorporated more than five years before the filing; principal office listed in New York, New York; revenue range: decline to disclose. (source)
  • Sales compensation recipient: Ladenburg Thalmann & Co. Inc. (CRD 505), soliciting in Illinois. (source)
  • Sales commissions $399,999 and finders' fees $0 reported in the filing. (source)

Timeline

  1. 2026-08-31: first sale in the offering, per the Form D. (source)
  2. 2026-09-14: Form D filed with the SEC ($4.98M sold). (source)

ibs.inc ↗

JUPITER NEUROSCIENCES, INC.

What they shipped

  • Homepage headline: "A clinical-stage drug platform company focused on treating neuroinflammation." (source)

Who is behind it

  • Christer Rosen: executive officer and director named in the Form D (Chief Executive Officer). (source)
  • Alison Silva: executive officer and director named in the Form D (Chief Operating Officer). (source)
  • Saleem Elmasri: executive officer named in the Form D (Chief Financial Officer). (source)
  • Marshall Hayward: executive officer and director named in the Form D (Chief Scientific Officer). (source)
  • Alexander Rosen: executive officer named in the Form D (Chief Administrative Officer). (source)
  • Nicholas Hemmerly: director named in the Form D. (source)
  • Holger Weiss: director named in the Form D. (source)
  • Andrew Cutler: director named in the Form D. (source)

Funding on file

  • The Form D filed on 2026-09-04 reports a $774,787 offering, $774,787 sold, $0 remaining, from 1 investor so far, all accredited. (source)
  • Terms in the filing: securities offered: equity; exemption claimed: Rule 506(b); offering expected to last more than a year: no. (source)
  • Issuer: Corporation organised in Delaware, incorporated more than five years before the filing; principal office listed in Palm Beach Gardens, Florida; revenue range: decline to disclose. (source)

Timeline

  1. 2026-08-20: first sale in the offering, per the Form D. (source)
  2. 2026-09-04: Form D filed with the SEC ($775K sold). (source)

jupiterneurosciences.com ↗

KeyCare, Inc.

What they shipped

  • Its own site describes it as: "KeyCare is a national virtual care organization built natively within Epic, giving health systems and plans a seamless way to extend access to high-quality, coordinated care. With a 50-state clinician network operating on the same EMR and workflows as its customer partners, KeyCare enables timely, efficient virtual care — from 24x7 on-demand visits to primary care and specialty services — all with" (source)

Who is behind it

  • Lyle Berkowitz: director named in the Form D. (source)
  • John Bertrand: director named in the Form D. (source)
  • Mark Bakken: director named in the Form D. (source)
  • Sebastian Caliri: director named in the Form D. (source)
  • William R. Cowen: director named in the Form D. (source)
  • Sulabh Agarwal: executive officer and director named in the Form D. (source)
  • Mike Robbins: executive officer named in the Form D. (source)
  • Has a careers page at https://keycare.org/Careers. (source)

Funding on file

  • The Form D filed on 2026-09-15 reports a $5,000,000 offering, $1,725,000 sold, $3,275,000 remaining, from 7 investors so far, all accredited. (source)
  • Terms in the filing: securities offered: debt; exemption claimed: Rule 506(b); offering expected to last more than a year: no. (source)
  • Issuer: Corporation organised in Delaware, incorporated more than five years before the filing; principal office listed in Chicago, Illinois; revenue range: decline to disclose. (source)

Timeline

  1. 2026-08-31: first sale in the offering, per the Form D. (source)
  2. 2026-09-15: Form D filed with the SEC ($1.73M sold). (source)

keycare.org ↗

Moonwalk Biosciences, Inc.

What they shipped

  • Its own site describes it as: "By deeply profiling and targeting the epigenetic code, Moonwalk aims to reprogram cells to their healthy state, fundamentally enabling a new approach to how therapies are discovered and developed." (source)
  • Homepage headline: "Transforming obesity treatment" (source)

Who is behind it

  • Alexander Aravanis: executive officer and director named in the Form D. (source)
  • Arash Jamshidi: executive officer and director named in the Form D. (source)
  • Chris Dimitropoulos: director named in the Form D. (source)
  • Paul Burton: director named in the Form D. (source)
  • Justin Valley: executive officer named in the Form D. (source)
  • Elaine Cheung: executive officer named in the Form D. (source)
  • Stephen Djedjos: executive officer named in the Form D. (source)
  • John Liles: executive officer named in the Form D. (source)
  • Has a careers page at https://moonwalk.bio/careers. (source)

Funding on file

  • The Form D filed on 2026-09-14 reports a $70,249,973 offering, $59,999,998 sold, $10,249,975 remaining, from 7 investors so far, all accredited. (source)
  • Terms in the filing: securities offered: equity; exemption claimed: Rule 506(b); offering expected to last more than a year: no. (source)
  • Issuer: Corporation organised in Delaware, incorporated in 2022; principal office listed in South San Francisco, California; revenue range: decline to disclose. (source)

Timeline

  1. 2026-08-26: first sale in the offering, per the Form D. (source)
  2. 2026-09-14: Form D filed with the SEC ($60.00M sold). (source)

moonwalk.bio ↗

Naba Health, Inc.

What they shipped

  • Its own site describes it as: "Naba Health is a healthcare services and technology company that powers the Mizan Clinic." (source)
  • Homepage headline: "Powering the Mizan Clinic" (source)

Who is behind it

  • Omar Ali Usman: executive officer and director and promoter named in the Form D. (source)
  • Has a careers page at https://naba.health/careers. (source)

Funding on file

  • The Form D filed on 2026-09-14 reports a $400,000 offering, $18,500 sold, $381,500 remaining, from 2 investors so far, all accredited. (source)
  • Terms in the filing: securities offered: simple agreement for future equity (safe); minimum investment accepted: $1,000; exemption claimed: Rule 506(b); offering expected to last more than a year: no. (source)
  • Issuer: Corporation organised in Delaware, incorporated in 2023; principal office listed in Fairfax, Virginia; revenue range: $1 - $1,000,000. (source)

Code

  • GitHub organization naba-health: 2 public repositories, account created 2023-07-28; most starred is ccpg (0 stars, Apache-2.0 licence); last push 2026-04-09. (source)

Timeline

  1. 2026-09-12: first sale in the offering, per the Form D. (source)
  2. 2026-09-14: Form D filed with the SEC ($19K sold). (source)

naba.health ↗

Pluri Inc.

What they shipped

  • Homepage description: "WHERETECHNOLOGYCOMESTO LIFE We leverage our cell expansion platform to create a collaborative network of ventures Scroll Down Scroll Down OUR MISSION Our patented technology harnesses the wisdom of nature to develop and manufacture next generation cell-based products across a range of industries." (source)

Who is behind it

  • Yaky Yanay: executive officer and director named in the Form D (Chief Executive Officer, President and Director). (source)
  • Liat Zalts: executive officer named in the Form D (Chief Financial Officer and Treasurer). (source)
  • Doron Shorrer: director named in the Form D. (source)
  • Rami Levi: director named in the Form D. (source)
  • Maital Shemesh-Rasmussen: director named in the Form D. (source)
  • Alexandre Weinstein: director named in the Form D (Chairman of the Board of Directors). (source)

Funding on file

  • The Form D filed on 2026-09-04 reports a $3,677,751 offering, $3,677,751 sold, $0 remaining, from 1 investor so far, all accredited. (source)
  • Terms in the filing: securities offered: options or warrants, securities issued on exercise of options; exemption claimed: Rule 506(b); offering expected to last more than a year: no. (source)
  • Issuer: Corporation organised in Nevada, incorporated more than five years before the filing; principal office listed in Haifa, Israel; revenue range: decline to disclose. (source)
  • Sales compensation recipient: A.G.P/ Alliance Global Partners (CRD 000003861), soliciting in New York. (source)

Timeline

  1. 2026-08-28: first sale in the offering, per the Form D. (source)
  2. 2026-09-04: Form D filed with the SEC ($3.68M sold). (source)

pluri-biotech.com ↗

Polyrizon Ltd.

What they shipped

  • Its own site describes it as: "Polyrizon is a biotech company, focused on the development and commercialization of innovative intranasal products based on the Company’s technology platforms." (source)

Who is behind it

  • Tomer Izraeli: executive officer and director named in the Form D (Chief Executive Officer and Director). (source)
  • Nir Ben Yosef: executive officer named in the Form D (Chief Financial Officer). (source)
  • Eyal Ron: executive officer named in the Form D (Chief Science Officer). (source)
  • Tidhar Turgeman: executive officer named in the Form D (Chief Technology Officer). (source)
  • Asaf Itzhaik: director named in the Form D. (source)
  • Oz Adler: director named in the Form D. (source)
  • Liat Sidi: director named in the Form D. (source)
  • Yehonatan Zalman Vinokur: director named in the Form D. (source)

Funding on file

  • The Form D filed on 2026-09-10 reports a $3,999,996 offering, $3,999,996 sold, $0 remaining, from 1 investor so far, all accredited. (source)
  • Terms in the filing: securities offered: options or warrants, securities issued on exercise of options; exemption claimed: Rule 506(b); offering expected to last more than a year: no. (source)
  • Issuer: Corporation organised in Israel, incorporated more than five years before the filing; principal office listed in Raanana, Israel; revenue range: decline to disclose. (source)
  • Sales compensation recipient: Aegis Capital Corp. (CRD 000015007). (source)
  • Sales commissions $320,000 and finders' fees $0 reported in the filing. (source)

Timeline

  1. 2026-09-03: first sale in the offering, per the Form D. (source)
  2. 2026-09-10: Form D filed with the SEC ($4.00M sold). (source)

polyrizon-biotech.com ↗

Rightway Healthcare, Inc.

What they shipped

  • Its own site describes it as: "Discover how Rightway" (source)
  • Homepage headline: "Stop choosing between employee health and your bottom line." (source)

Who is behind it

  • Jordan Feldman: executive officer and director named in the Form D. (source)
  • Theodore Feldman: executive officer and director named in the Form D. (source)
  • Jonathan Locker: director named in the Form D. (source)
  • Kareem Zaki: director named in the Form D. (source)
  • Samir Kaul: director named in the Form D. (source)
  • Michael Lynton: director named in the Form D. (source)
  • Has a careers page at https://www.rightwayhealthcare.com/careers. (source)

Funding on file

  • The Form D filed on 2026-09-08 reports a $154,999,891 offering, $154,999,891 sold, $0 remaining, from 6 investors so far, all accredited. (source)
  • Terms in the filing: securities offered: equity; exemption claimed: Rule 506(b); offering expected to last more than a year: no. (source)
  • Issuer: Corporation organised in Delaware, incorporated more than five years before the filing; principal office listed in New York, New York; revenue range: decline to disclose. (source)

Timeline

  1. 2026-08-25: first sale in the offering, per the Form D. (source)
  2. 2026-09-08: Form D filed with the SEC ($155.00M sold). (source)
  3. 2023-05-05: "Strengthening the scale with healthcare navigation solutions. (2022)" on Hacker News by mooreds, 2 points and 0 comments. (source)
  4. 2017: founding date the site gives in its own structured data. (source)

rightwayhealthcare.com ↗

Tenon Medical, Inc.

What they shipped

  • Its own site describes it as: "The Catamaran SI Joint Fusion System offers a less-invasive approach to delivering significant & sustained reduction in SI joint pain with their SI joint implant." (source)
  • Homepage headline: "Catamaran SI Joint Fusion System MAINSAIL™ Study:" (source)

Who is behind it

  • Ivan Howard: director named in the Form D. (source)
  • Kristine M. Jacques: director named in the Form D. (source)
  • Robert K. Weigle: director named in the Form D. (source)
  • Steven H. Hochschuler: director named in the Form D. (source)
  • Steven M. Foster: executive officer and director named in the Form D (Chief Executive Officer and President, Director). (source)
  • Richard Ginn: executive officer and director named in the Form D (Chief Technology Officer, Director). (source)
  • Kevin Williamson: executive officer named in the Form D (Chief Financial Officer). (source)
  • Wyatt D. Geist: executive officer named in the Form D (Chief Innovation Officer). (source)

Funding on file

  • The Form D filed on 2026-09-04 reports a $3,000,000 offering, $3,000,000 sold, $0 remaining, from 1 investor so far, all accredited. (source)
  • Terms in the filing: securities offered: equity, options or warrants, securities issued on exercise of options; exemption claimed: Rule 506(b); offering expected to last more than a year: no. (source)
  • Issuer: Corporation organised in Delaware, incorporated more than five years before the filing; principal office listed in Los Gatos, California; revenue range: decline to disclose. (source)
  • Sales compensation recipient: WallachBeth Capital LLC (CRD 000147853), soliciting in New York. (source)
  • Sales commissions $275,000 and finders' fees $0 reported in the filing. (source)

Timeline

  1. 2026-08-27: first sale in the offering, per the Form D. (source)
  2. 2026-09-04: Form D filed with the SEC ($3.00M sold). (source)

tenonmed.com ↗

Theia Imaging LLC

What they shipped

  • Its own site describes it as: "Theia Imaging provides advanced ophthalmic imaging diagnostics accessible to populations unable to access conventional tabletop clinical imaging." (source)
  • Homepage headline: "BRINGING ADVANCED OPHTHALMIC IMAGING" (source)

Who is behind it

  • Al-Hafeez Zahir Dhalla: executive officer and director named in the Form D. (source)
  • Christian Blake Viehland: executive officer and director named in the Form D. (source)
  • Cynthia Ann Toth: executive officer and director named in the Form D. (source)

Funding on file

  • The Form D filed on 2026-09-17 reports a $1,000,000 offering, $160,000 sold, $840,000 remaining, from 3 investors so far, all accredited. (source)
  • Terms in the filing: securities offered: safe (simple agreement for future equity); minimum investment accepted: $50,000; exemption claimed: Rule 506(b); offering expected to last more than a year: no. (source)
  • Issuer: Limited Liability Company organised in North Carolina, incorporated more than five years before the filing; principal office listed in Durham, North Carolina; revenue range: decline to disclose. (source)

Timeline

  1. 2026-09-09: first sale in the offering, per the Form D. (source)
  2. 2026-09-17: Form D filed with the SEC ($160K sold). (source)

theiaimaging.com ↗